Developing Assays for Novel Drugs

Get in Touch

Our Locations

Developing Assays for Novel Drugs

Current science regarding hybrid assays, why they are considered the next "big thing," the technical challenges, and the regulatory impact of these assays.

Novel drugs with complex design are becoming more common to treat difficult diseases.

This insight brief, authored by Michael Brown, Ph.D., Senior Director, Immunoanalytical Services and Barry Jones, Ph.D., Director, LC-MS Biologics and Biomarkers, provides an overview of the development of assays for these novel drugs including where the field may be moving in the future.

Complete the form below to access this insight brief

Related Services & Solutions

Related Thought Leaders Insights

Scientific Poster

Robust performance of single-cell multiomic analysis (CITE-Seq) demonstrated across multiple locations, replicates, and donors on challenging cryopreserved PBMC and BMMC samples

Q² Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-Seq with BioLegend. Describes CITE-Seq performance expectations for...

Brochure

Challenging Bioanalytical Work

If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...

Factsheet

CNS Biomarkers

Rules-Based Medicine, a Q² Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...